Approach to latent tuberculosis infection screening before biologic therapy in ibd patients: Ppd or igra?
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Abstract
The use of biological agents for the treatment of chronic inflammatory conditions such as inflammatory bowel diseases (IBD) has been on the rise.1,2 Current biological therapies include antitumor necrosis factor-A (anti-TNF-A), anti-interleukin-12/23, and anti-integrin agents. Before initiation of biological drugs, screening for Mycobacterium tuberculosis infection is required to avoid reactivation or worsening of disease after immunosuppression. It has been shown that anti-TNF-A treated patients have a 14-fold increased risk of tuberculosis (TB) infection/reactivation compared with healthy controls.3 The methods for screening for TB have evolved over time and vary from region to region. © 2020 Oxford University Press. All rights reserved.
Description
Keywords
Biologic therapy, Igra, Ppd, Quantiferon-gold, Adult, Biological therapy, Female, Gastroenterology, Humans, Inflammatory bowel diseases, Interferon-gamma release tests, Latent tuberculosis, Male, Mass screening, Mycobacterium tuberculosis, Practice guidelines as topic, Tuberculin test, Bcg vaccine, Infliximab, Tuberculin, Accuracy, Bcg vaccination, Cd8+ t lymphocyte, Crohn disease, Disease severity, Enzyme linked immunosorbent assay, Human, Infection prevention, Infection risk, Inflammatory bowel disease, Interferon gamma release assay, Medication therapy management, Priority journal, Review, Screening test, Tuberculosis, Ulcerative colitis, Adverse event, Microbiology, Practice guideline, Procedures